This site is intended for healthcare professionals only

DiabetesontheNet Logo
×

Journal of
Diabetes Nursing

Issue:

Share this article
Share on facebook
Share on twitter
Share on email
Share on print

COVID-19: How to switch from twice-daily to once-daily basal insulin

In the COVID-19 pandemic, there may be a need to re-evaluate the insulin regimens of people with type 2 diabetes who require nursing visits for insulin administration, in order to reduce contact and risk of contamination and to reduce demand for community nursing services. This guide outlines how to switch from a twice-daily to a once-daily basal insulin regimen.

Important notes: This guide is intended to assist with insulin management in people with type 2 diabetes, not type 1 diabetes.

Insulin initiation and adjustment should only be undertaken and overseen by healthcare professionals with the relevant expertise and training.

In light of the current COVID-19 pandemic, there has become a need to re-evaluate the insulin regimens of people in care and residential homes and those who require district nursing visits for insulin administration. This need has arisen in order to reduce contact and therefore reduce risk of contamination, and also to address the current increase in demand for community nursing services.

Many older and frail people remain on twice-daily insulin regimens: either twice-daily NPH insulin or mixed insulin. As people become increasingly frail, it is good practice to review their insulin regimen in order to reduce the risk of hypoglycaemia and daily glycaemic variability. Where once a twice-daily regimen was necessary to achieve their individual targets, as frailty increases it may be more appropriate and safer to use a once-daily basal regimen.

Recommended daily analogue insulins:

  • Abasaglar® (glargine)
  • Lantus® (glargine)
  • Semglee® (glargine)
  • Toujeo® (glargine 300 units/mL)
  • Tresiba® (degludec)

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
Related content
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
DiabetesontheNet Logo
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.